Home Department: Bioengineering
Supported by: Bio-X
Mentors: Calvin Kuo, Medicine (Hematology); and Stanley Qi, Bioengineering and Chemical & Systems Biology

To advance the development of cancer treatments, The Cancer Genome Atlas (TCGA) has carried out genome scale DNA sequencing efforts of a variety of cancers to identify novel druggable targets; however, these data require functional validation in a biological system. Daniel Hart will use the CRISPR/Cas9 system for genetic screens in primary organoid culture to identify key drug targets in esophageal cancer by conducting loss of function and gain of function screens.

Poster presented at the Stanford Bio-X Interdisciplinary Initiatives Symposium on August 24, 2016:

Engineering Screening Approaches to Validate Cancer Driver Genes

Daniel Hart¹, Sean de la O¹, Antonia Dominguez², Ameen Salahudeen¹, Stanley Qi², Calvin Kuo¹
[Departments of Medicine (Division of Hematology)¹ and Bioengineering², Stanford University]